Rituximab monotherapy is highly effective in splenic marginal zone lymphoma

Hematological Oncology

Volumn 25, Issue 3, 2007, Pages 127-131

  Kalpadakis, C ^a,b   Pangalis, Gerassimos A ^a   Dimopoulou, M N ^a   Vassilakopoulos, T P ^a   Kyrtsonis, M C ^a   Korkolopoulou, P ^a   Kontopidou, F N ^a   Siakantaris, M P ^a   Dimitriadou, E M ^a   Kokoris, S I ^a   Tsaftaridis, P ^a   Plata, E ^a   Angelopoulou, M K ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

Author keywords

Marginal zone lymphoma; Rituximab; Splenic; Treatment

Indexed keywords

CHLORAMBUCIL; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; BACKACHE; BLOOD CELL COUNT; BONE MARROW BIOPSY; BRONCHOSPASM; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPHOCYTOSIS; MALE; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; RIGOR; SPLEEN CANCER; SPLENIC MARGINAL ZONE LYMPHOMA; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SPLENIC NEOPLASMS; TREATMENT OUTCOME;

EID: 34848837286     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.820     Document Type: Article

References (24)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
3. Chacon JI, Mollejo M, Munoz M, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostics factors in a series of 60 patients. Blood 2002; 100: 1648-1654.
4. Parry-Jones N, Matutes E, Gruszca-Westwood AM, Swansbury GJ, Wotherspoon AC, Catovsky D. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol 2003; 120: 759-764.
5. Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma 2002; 3: 41-47.
6. Franco V, Florena AM, Stella M, et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer 2001; 91: 294-301.
7. Thieblemont C. Clinical presentation and management of marginal zone lymphomas. ASH Educ Book 2005; 307-314.
8. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102: 2741-2745.
9. Ferreri AJ, Ponzoni M, Martinelli G, et al. Rituximab in patients with mucosa-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica 2005; 90: 1578-1579.
10. Derksen PWB, Langerak AW, Kerkhof E, et al. Comparison of different polymerase chain reaction-based approaches for clonality assessment of immunoglobulin heavy-chain gene rearrangements in B-cell neoplasia. Mod Pathol 1999; 12: 794-805.
11. Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes. Clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol 1996; 93: 731-736.
12. Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/ splenic marginal-zone lymphoma. Semin Hematol 1999; 36: 148-154.
13. Lefrere F, Hermine O, Belanger C, et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 2000; 14: 573-575.
14. Pangalis GA, Vassilakopoulos TP, Kalpadakis Ch, et al. Treatment of indolent lymphomas from watch and wait to high dose therapy. Hematology 2005; 1: 6-9.
15. Riccioni R, Caracciolo F, Galimberti S, Cecconi N, Petrini M. Low dose 2-CdA schedule activity in splenic marginal zone lymphomas. Hematol Oncol 2003; 21: 163-168.
16. Lefrerre F, Hermine O, Francois S. et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 2000; 40: 113- 117.
17. Bolam S, Orchard J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol 1997; 99: 158-161.
18. Raderer M, Jager G, Brugger S, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 2003; 65: 306-310.
19. Pangalis GA, Kyrtsonis M-C, Vassilakopoulos TP, et al. Immunotherapeutic and immunoregulatory drugs in haemotologic malignancies. Curr Top Med Chem 2006; 6: 1657-1686.
20. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23: 1979-1983.
21. McLaughlin P, Grillo Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
22. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101-106.
23. Bennett M, Sharma K, Yegena S, Gavish I, Dave H, Schechter G. Rituximab monotherapy for splenic marginal zone lymphoma. Haematol/Haematol J 2005; 90: 856-858.
24. Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006; 107: 125-135.